GSHD · Goosehead Insurance, Inc. · Stock research

Current Thesis

De-rated insurance-distribution compounder. Spot ~$52.69 (2026-07-02 close), down ~58% over the trailing twelve months from a $105 peak, inside a 52-week range of $33.68–$105.01. The push into the low-$50s is a countertrend bounce off the $33.68 low, an oversold rebound within a broken longer-term downtrend. Q1 2026 (reported 2026-04-22) was a clean growth quarter the tape refused to reward. The insurtech/personal-lines-distribution theme is maturing rather than leading, and there is no accelerating leg to buy ahead of the ~2026-07-22 Q2 print, which is the next binary.

Bullish and bearish views on Goosehead Insurance, Inc.

The model's bull view on Goosehead Insurance, Inc. (GSHD), in brief: Q1 2026 (2026-04-22): total revenue +23% YoY to $93.1M; core revenue +15% to $79.5M; total written premium +13% to $1.1B; policies in force +14% to ~1,973,000. The bear view: Price structure is broken: -58% over twelve months and roughly -31% over the last 90 days into the low-$50s. Both cases follow in full.

Bull Case

• Q1 2026 (2026-04-22): total revenue +23% YoY to $93.1M; core revenue +15% to $79.5M; total written premium +13% to $1.1B; policies in force +14% to ~1,973,000.
• New business commissions grew ~29% in Q1 2026 the fastest franchise pace in nearly five years per company commentary, evidence the flywheel is still turning at the producer level.
• Average producers per franchise expanded to 2.3 from 1.9 a year prior unit productivity rising even as headline producer count (2,150, +3% YoY) is flattish.
• Multiple already reset: forward P/E ~24 against trailing ~48; the premium the 2021–2024 story carried has largely compressed, so a re-rate no longer needs a heroic multiple.
• Sell-side floor holds: UBS reiterated Buy on 2026-06-09 while trimming its target to $67; consensus targets cluster ~$65–71 versus ~$52 spot, with a high mark of $125.
• FY2026 guide intact at organic total-revenue growth of 10–19% and written-premium growth of 12–20% double-digit compounding for a $382M-TTM-revenue base.

Bear Case

• Price structure is broken: -58% over twelve months and roughly -31% over the last 90 days into the low-$50s. A tape shaped like this is distributing, and the current bounce sits under a firmly downward-sloping trend from $105.
• Growth is decelerating against its own history core revenue +15% and an FY guide of 10–19% for a business that printed 30–40%+ in prior years. When a compounder's growth eases, its multiple follows, and that repricing may not be finished.
• Franchise base is thinning at the unit level: 10 exits and 63 consolidations in Q1 2026 against just 20 launches, with total producers up only 3% YoY.
• Trailing P/E ~48 is not a bargain despite the drawdown; net income was roughly flat YoY (TTM ~$30M) and EPS slipped, so the derate has fundamental support.
• Analyst dispersion is wide targets span $43 to $125 with a split rating book (roughly 6 Buy / 6 Hold / 1 Sell) meaning no consensus conviction to pull the price higher.
• The ~2026-07-22 Q2 print lands on a name with no momentum cushion; a soft guide or a slowing new-business-commission number reprices it lower quickly.

Setup & Price Structure

Spot ~$52.69 (2026-07-02). The rally from the 52-week low of $33.68 into the low-$50s is a mean-reversion move off a 65%-off-high washout, not fresh-money accumulation into a breakout the stretched short-term momentum reading came from that snap-back, not from a trend igniting. The weekly structure still shows a series of lower highs from $105 and no reclaimed prior base. The bounce is unconfirmed by the group: insurtech distribution is maturing, and peers are not breaking out alongside it. For a narrative-momentum book, strength here is countertrend, not the setup this playbook exists to catch. The first genuine evidence of a trend change would be a pullback that carves a higher low in the mid-$40s and then reclaims the low-$60s on expanding volume; the current tape shows none of that.

Catalyst Calendar (next 30 days)

• ~2026-07-22 (est.) Q2 2026 earnings, the dominant event in the window. Watch whether the FY organic revenue-growth guide (currently 10–19%) is raised or cut, whether new-business commissions hold near the +29% Q1 pace, and the franchise launch/exit/consolidation ratio versus Q1's 20/10/63.
• No FDA/PDUFA dates, index reconstitution events, or scheduled analyst days inside the next 30 days.

What Would Change Our Mind

• A weekly reclaim of the low-$60s that recovers a broken shelf on rising volume, with insurtech-distribution peers turning up together that would flip the read from countertrend bounce to trend change and justify a probe.
• A Q2 print on ~2026-07-22 that lifts the FY guide above the 10–19% band while new-business commissions hold ~+29% narrative reacceleration that the tape can front-run.
• Clustered insider buying beyond the two prior purchases, or a fresh analyst upgrade cycle reversing the 2026-06-09 UBS target cut sell-side chasing rather than trimming.

Correlation Notes

• Moves with personal-lines insurance distribution and insurtech peers; a P&C rate-softening or premium-deceleration cycle pressures growth optics across the entire cohort at once.
• Rate-sensitive growth/duration profile: the multiple expands in falling-rate regimes and compresses when rates and risk premia rise, so macro repricing hits it harder than a slow-grower.
• Idiosyncratic franchise-execution risk producer recruiting, consolidation pace, corporate-vs-franchise mix can decouple it from the group around the earnings print.